Type 2 Diabetes Drugs: SGLT2 Inhibitors

Free Case Evaluation

Are you using an SGLT2 Inhibitor drug and experiencing serious side effects? If so, you may have grounds for a personal injury claim. Other patients are reporting serious issues after using these drugs.

Type 2 sodium-glucose co-transporter (SGLT2) inhibitors are newer drugs used to treat Type 2 diabetes.  The SGLT2 inhibitor class of antidiabetic medications is also sometimes known as the “gliflozins” and includes the drugs:

  • Invokana (canagliflozin) – made by Janssen, a division of Johnson & Johnson
  • Farxiga (dapagliflozin) – co-marketed in Europe and the U.S by Bristol-Myers Squibb and AstraZeneca

Two of these drugs are also available in combination form with another antidiabetic medication, metformin. These are sold under the brand names Invokamet (canagliflozin / metformin) and Xigduo XR (dapagliflozin / metformin.  

Manufacturers of SGLT2 Inhibitors

Johnson & Johnson, based in New Jersey, is the largest pharmaceutical company in the U.S. with estimated annual sales of over $72 billion.  

AstraZeneca is based in London and has annual sales of over $26 billion and Bristol-Myers Squibb is based in New York with annual revenue of $20 billion.  

Boehringer Ingelheim is based in Ingelheim, Germany and has annual sales of $15 billion and its co-marketer, Indiana-based Eli Lilly has annual revenue of $20 billion.

The number of SGLT2 side effects claims continues to grow, with more patients coming forward sharing their concerns.

About Type 2 Diabetes

Diabetes is a medical condition in which the body does not process sugar correctly.  Over time, excessive glucose levels in the bloodstream may damage organs. The damaged organs may include the eyes, kidneys, and skin. These are resulting in blindness, kidney failure, and the necessity for amputation of the feet and legs.

Type 2 diabetes is the most common and affects up to 28 million Americans.  It is often related to obesity and may contribute to a number of additional disease including hypertension, high cholesterol levels and cardiovascular death.

In normal people, insulin helps to transport glucose or sugar from the bloodstream into the cells, where it can be used as energy.  Type 2 diabetics may not produce enough insulin, or the blood cells may have become resistant to insulin – leaving much of the sugar in the bloodstream.

Antidiabetic medication has traditionally worked by increasing the production of insulin. These drugs assist with increasing the body’s sensitivity to insulin or by preventing insulin from being absorbed in the intestines.  

As newer medications, SGLT2 inhibitors antidiabetics work differently from other antidiabetic medications. Those patients who struggled with other medications were given these instead, but many are suffering serious SGLT2 side effects and filing lawsuits.

SLGT2 Inhibitor Actions

When the kidneys work normally in a non-diabetic patients, extra glucose in the bloodstream filters from the blood and is reabsorbed back into the bloodstream by the kidney “tubules” where it can be used as energy.

As type 2 diabetics have too much glucose in the blood, SGLT2 inhibitors prevent the kidneys from reabsorbing that glucose so that it is passed out of the body in the urine.  SGLT2 inhibitors result in over 100 grams of sugar being excreted into the urine. This is the same as excreting over 400 calories, causing some people to lose weight.

Side Effects

All medications have side effects, most of which are mild to moderate.  The SGLT2 inhibitors have a number of serious side effects that can even be life-threatening.

Common side effects of SGLT2 inhibitors include:

  • Yeast infections including vaginal, vulvar and penile (banal) infections
  • Urinary tract infection including bladder and kidney infections
  • Intolerance to the sun
  • Rash and itching, often from yeast infection on skin
  • Nausea
  • Fatigue or loss of energy

More severe side effects of SGLT2 inhibitors may warrant emergency medical action.

Diabetic Ketoacidosis

The Food and Drug Administration (FDA) issued a medical warning in May 2015 regarding the risk of diabetic ketosis (DKA) in patients taking SGLT2 inhibitors including Invokana and Farxiga.  Between March 2013 and April 2014, at least 20 cases of DKA had been reported to the FDA.

Diabetic ketoacidosis is caused by high levels of ketones in the bloodstream which are produced by the body when it is unable to use glucose in the cells. The ketones are a byproduct of fat metabolism and are acidic in nature.  The disorder can quickly deteriorate and become life-threatening.

Symptoms of diabetic ketoacidosis or ketosis may include:

  • Increased thirst and urination
  • Excessive hunger
  • Abdominal pain or nausea
  • Fatigue, Weakness, Dizziness
  • Shortness of breath, Sweating, Rapid heart beat
  • “Fruity” odor to the breath

If the patient does not receive treatment, the following symptoms may occur:

  • Confusion or extreme irritability
  • Vomiting
  • Dizziness or Fainting
  • Trouble breathing
  • Unconsciousness

If left untreated, diabetic ketoacidosis is life-threatening.

Unfortunately, many Type 2 diabetics will not recognize the symptoms and the original prescribing information and patient instructions did not list diabetic ketoacidosis as a concern.

Other Serious Side Effects

In addition, the medical data company, IMS has identified hundreds of additional serious adverse events that occurred in patients who took the newer SGLT2 inhibitor antidiabetic medications.  The newer diabetic medications may also cause:

  • Low blood pressure
  • Changes in laboratory blood levels of potassium, cholesterol, hemoglobin and others
  • Decreased kidney function
  • Allergic reactions

Data shared in early 2017 by the European Medicines Agency found a high risk of toe amputation for those individuals using SGLT2 inhibitors.

In January, 2017, research was published in Diabetes Care showing that patients taking SGLT2 inhibitors may suffer the risk of renal injury.

Some medical professionals, including several FDA advisory committee members have expressed concern about an increased risk of heart attack and companies have been ordered to complete additional safety studies of the effects on the heart, bones, and liver and to look into the risk of cancer and pregnancy risk.

SGLT2 Warnings

Farxiga was the first SGLT2 drug the FDA considered for approval.  The application was initially denied based on a concern about liver failure.  

Invokana was approved in March 2013 after an FDA advisory panel voted 10 to 5 for approval though some advisory panel members expressed concern about the drug’s potentially increased risk for heart attack.  Farxiga was finally approved in January of 2014.

In January of 2013, the consumer advocacy group, Public Citizen, filed an objection to Invokana.  The group stated that not enough safety information was available about the medication and that prior “new” antidiabetic drugs had proven troublesome.  Many of these drugs have resulted in thousands of lawsuits due to serious adverse events caused by the medications.

Public Citizen has also objected to advertising regarding the SGLT2 medications stating that “reduced blood pressure” as claimed by the medication’s marketing material is not a benefit, but a potentially harmful side effect as described in the literature.  

They have also objected to the non-approved claim that “some” patients may lose weight on these medications as the notification often appears close to the approved indications which the group feels may be confusing and cause some to believe the medication is approved for use as a weight loss agent.  Public Citizen has all three medications on its “Do Not Use” list on its website.

FDA Reactions to SGLT2 Inhibitor Side Effects and Risks in 2015 and Beyond

In May 2015, the FDA issued a warning letter regarding the risk of diabetic ketoacidosis, citing 20 serious adverse events reports the agency had received.  Prescribing information for the medications has listed a “contraindication” (reason against use) for patients with DKA but literature contains no clear warning about the risk.

In addition, serious adverse event reporting is “voluntary” and more cases of SGLT2-related DKA may exist and additional events may yet occur.  In 2014, an estimated 2 million Invokana prescriptions were filled and Farxiga was the 8th best-selling new prescription medication.

Farxiga and Invokana Lawsuits

In the recent past, thousands of lawsuits have been filed and settled for newer antidiabetic medications which have caused medical injury.

It is not yet known how many patients may be injured by the SGLT2 inhibitors but IMS health data indicates that thousands of serious adverse events including diabetic ketoacidosis may be expected.

Injury caused by drugs, like those for diabetes, may result in a need for expensive medical treatments, hospitalization and long-term medical care.  Those patients may be eligible to recover money for medical costs, lost wages, future medical treatments and pain and suffering.  In some cases, the families of victims who die after using certain medications may be eligible for compensation for wrongful death.

Each occurrence of medical injury that is thought to be caused by a drug must be considered individually as the facts for each case are different.  In some cases, patients have been eligible for thousands or even millions of dollars compensation.  There is no guarantee of award.

View Sources

  1. American Diabetes Association, (10 June 2014), Statistics About Diabetes, ADA Diabetes.org, Accessed on 08 June 2015 http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav
  2. AstraZeneca and Bristol-Myers Squibb, (13 January 2014), US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes, AstraZeneca, Accessed on 08 June 2015 http://www.astrazeneca.com/Media/Press-releases/Article/13012014–us-fda-approves-farxiga-dapagliflozin
  3. Berkot, B., (15 May 2015), FDA warns on newer class of type 2 diabetes drugs, Reuters, Accessed on 08 June 2015 http://www.reuters.com/article/2015/05/15/us-fda-diabetes-idUSKBN0O01P520150515
  5. Brooks, M., (15 May 2015), SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA, Medscape Pharmacists, Accessed on 08 June 2015 http://www.medscape.com/viewarticle/844754
  6. FDA prescribing information, Farxiga Prescribing Information, Drugs.com, Accessed on 08 June 2015 http://www.drugs.com/pro/farxiga.html
  8. FDA prescribing information, Invokana Prescribing Information, Drugs.com, Accessed on 08 June 2015 http://www.drugs.com/pro/invokana.html
  9. Fiore, K., SGLT2 Inhibitors May Up Glucose Production, MedPage Today, Accessed on 08 June 2015 http://www.medpagetoday.com/Endocrinology/Diabetes/44014
  10. Food and Drug Administration (15 May 2015), FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, U.S. Food and Drug Administration, Accessed on 08 June 2015 http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
  11. Hahn, P., (19 August 2014), Part 2: “IT’S A NIGHTMARE”: After the Avandia debacle, is history about to repeat itself?, Canada Free Press, Accessed on 08 June 2015 http://canadafreepress.com/index.php/article/65394
  12. Huston, L., (29 March 2013), FDA Approves First SGLT2 Inhibitor For Diabetes, Forbes, Accessed on 08 June 2015 http://www.forbes.com/sites/larryhusten/2013/03/29/fda-approves-first-sglt2-inhibitor-for-diabetes/
  13. Janssen Pharmaceutica (26 May 2014) First-in-Class Type 2 Diabetes Medication Approved in Canada – INVOKANA offers a new approach to treatment, Janssen.ca, Accessed on 08 June 2015 http://www.janssen.ca/subcategory_docdownload?id=sites/default/files/about_us_media/INVOKANA%20Launch%20News%20Release%20FINAL.pdf
  14. LaMattina, J., (13 April 2015), Should the FDA Require CV Outcome Studies for Diabetes Drugs Before Approval? Forbes, Accessed on 08 June 2015 http://www.forbes.com/sites/johnlamattina/2015/04/13/should-the-fda-require-cv-out come-studies-for-diabetes-drugs-before-approval/
  15. MacDonald, E., (01 April 2015), FDA Urged to Fine Drugmakers Over Ads, FoxBusiness, Accessed on 08 June 2015 http://www.foxbusiness.com/economy-policy/2015/04/01/fda-urged-to-fine-drugmakers-over-ads/
  16. Matsuyama, K., et al (2013, January 28). Takeda jumps after winning FDA approval for diabetes drug. Bloomberg. Retrieved from http://www.bloomberg.com/news/2013-01-28/takeda-diabetes-drug-succeeding-actos-wins-fda-approval.html
  17. Mayo Clinic Staff (12 October 2012), Diabetic Ketoacidosis, Mayo Clinic, Accessed on 08 June 2015 http://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/basics/complications/con-20026470
  18. Mayo Clinic Staff, (24 July 2014), Type 2 diabetes, Treatments and drugs, Mayo Clinic, Accessed on 08 June 2015 http://www.mayoclinic.org/diseases-conditions/type-2-diabetes/basics/treatment/con-20031902
  19. Public Citizen, (10 January 2013), FDA Should Reject Dangerous Diabetes Medication, Public Citizen Tells Advisory Committee, Public Citizen, Accesse on 08 June 2015 http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=3793
  20. Rodale, M., (06 April 2014), The Worst New Drug of 2014, Huffington Post, Accessed on 08 June 2015 http://www.huffingtonpost.com/maria-rodale/the-worst-new-drug-of-201_b_4723514.html
  21. Sun, L., (15 January 2014), 3 ways Johnson & Johnson is Revolutionizing Diabetes, Motley Fool, Accessed on 08 June 2015 http://www.fool.com/investing/general/2014/01/15/3-ways-johnson-johnson-is-revolutionizing-diabetes.aspx
  22. Tauchi, K., Accessed on 08 June 2015, 10 deaths reported following use of newly marketed diabetes drugs, The Asahi Shimbun, Accessed on 08 June 2015 http://ajw.asahi.com/article/behind_news/social_affairs/AJ201501090058
  23. Team, T., (20 May 2015), FDA’s New Warning About Invokana May Not Matter Much For J&J; Let’s Focus On Pipeline Instead, Forbes, Accessed on 08 June 2015 http://www.forbes.com/sites/greatspeculations/2015/05/20/fdas-new-warning-about-invokana-may-not-matter-much-for-jj-lets-focus-on-pipeline-instead/
  24. Thomas, K., FDA Advisory Panel Votes to Approve Diabetes Drug, New York Times, Accessed on 08 June 2015 http://www.nytimes.com/2013/01/11/business/fda-advisory-panel-votes-to-approve-diabetes-drug.html?partner=rss&emc=rss&_r=0
Have you been affected by a drug or device listed? Call 855-543-7559